SubscribeAll Posts Tagged With: "phase III"
This Bet Pays Off More Than 80% of the Time
You would have made 78% in one day…
Last month, a small biotech company – Synta Pharmaceuticals – suffered a huge drop in its share price. The company announced its lead drug, which treats skin cancer, failed in a pivotal Phase III trial. The stock dropped 78%…
Short sellers profit when stocks crash. And investors who "shorted" Synta’s – who bet against the drug’s approval – walked away with a big paycheck. But shareholders who stuck by Synta were probably shocked…
Synta’s management had done everything right. It ran a "placebo controlled" Phase II trial (that’s the middle hurdle) before it went to…
13Mar2009 | Stansberry and Associates | 0 comments | ContinuedInvesting in Biotech: How to Profit from the 3 “Phases” of Clinical Trials
When it comes to investing in biotech, Marc Lichtenfeld is one of the smartest analysts in the field. He’s a pro at finding companies in this group that consistently outperform. But more importantly, I trust his opinion. Today, he’s showing us how a drug is brought to market, and the best way to profit from these announcements.
~ Alexander Green
Investing in biotech can be incredibly exciting and rewarding. After all, there’s nothing like getting in early on a company with a novel drug for cancer, diabetes or any other debilitating disease – watching the drug successfully navigate clinical trials and then…
2Sep2008 | Investment U | Comments Off | ContinuedBiotech Stocks: Opportunities abound for Osiris Therapeutics (OSIR:NASDAQ)
‘This Maryland-based biotechnology firm develops treatments for conditions as varied as Crohn’s disease, knee arthritis, tissue damage, life-threatening Graft-versus-host disease and acute radiation syndrome.’ – Laura Cadden
Osiris Therapeutics, Inc. creates therapeutic drugs from human mesenchymal stem cells (MSCs) retrieved from bone marrow donated by healthy adult volunteers.
Bone regeneration = big bucks
Earlier this month, Osiris announced the sale of its Osteocel unit to NuVasive for $85 million.
Osteocel promotes bone regeneration and is used in spinal fusion and other orthopedic procedures.
This deal provides Osiris with the money and ability to focus on the next generation of revolutionary products… products like Chondrogen, which works…
27May2008 | Laura Cadden | 1 comment | ContinuedProfit Opportunity: A diamond in a mud pit
This is a very scary period of time for investors. Just when they think they have the market figured out, it turns out to be a head fake and the market changes track.
If not careful, this market could become more than scary. It could be come downright dangerous. For many investors, it already has. The losses are piling up.
Across the nation, investors are running for cover. Nearly all economic barometers show a recession on the horizon. It is time to head to your storm shelters. When the markets are destined for a major slowdown, you need to take action.
Unfortunately, the…
4Apr2008 | Guest Contributor | Comments Off | Continued
Loading ...
